PTCT Q1 2023 Earnings — PTC Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTCTPTC Therapeutics, Inc.

$6B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$220M+48.2% YoY

Gross Profit

$206M93.6% margin

Operating Income

-$118M-53.4% margin

Net Income

-$139M-63.1% margin

EPS (Diluted)

$-1.88

QoQ Revenue Growth

+31.6%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$73M

Stock-Based Comp.

$29M

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$2.1B

Stockholders' Equity

-$458M

Cash & Equivalents

$167M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$220M	$149M	+48.2%
Gross Profit	$206M	$139M	+48.8%
Operating Income	-$118M	-$87M	-35.9%
Net Income	-$139M	-$127M	-9.7%

Revenue Segments

Manufacturing

$2M100%

Geographic Segments

Non-US

$115M68%

United States

$55M32%